The role of distinct p185neu extracellular subdomains for dimerization with the epidermal growth factor (EGF) receptor and EGF-mediated signaling

The extracellular domain of p185c-neu can be viewed as a complex structure of four subdomains, two of which are cysteine-rich subdomains. We have investigated the contribution of these distinct p185c-neu extracellular subdomains to p185/epidermal growth factor receptor (EGFR) heteromer formation and EGF-induced heteromeric signaling. Our studies indicate that at least two separate p185 subdomains, a region spanning subdomains I and II and subdomain IV are involved in association of p185 with the EGFR. We also demonstrated that subdomain IV reduced the heteromeric signaling and transforming activities induced by EGF after associating with EGFR. When 126 aa were deleted from subdomain IV, this small subdomain IV-derived fragment could still lead to heterodimers with EGFR and suppress EGF-induced mitogen-activated protein kinase activation and subsequent transformation abilities. These data provide information about trans-inhibitory mechanisms of mutant p185 species and also indicate that both the entire and a part of subdomain IV may represent a therapeutic target for erbB-overexpressing tumors. Finally, these studies define a basic feature of receptor-receptor associations that are determined by cystine-knot containing subdomains.

[1]  M. Lemmon,et al.  Extracellular domains drive homo‐ but not hetero‐dimerization of erbB receptors , 2000, The EMBO journal.

[2]  Monilola A. Olayioye,et al.  The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[3]  David C. Lee,et al.  Mutagenesis Reveals a Role for Epidermal Growth Factor Receptor Extracellular Subdomain IV in Ligand Binding* , 1999, The Journal of Biological Chemistry.

[4]  J. Adelman,et al.  The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Cardiff,et al.  Elevated expression of activated forms of Neu/ErbB‐2 and ErbB‐3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer , 1999, The EMBO journal.

[6]  D. O’Rourke,et al.  Domain-specific Interactions between the p185 neu and Epidermal Growth Factor Receptor Kinases Determine Differential Signaling Outcomes* , 1999, The Journal of Biological Chemistry.

[7]  D. O’Rourke,et al.  Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: implications for subdomain contributions to receptor assembly , 1998, Oncogene.

[8]  R. Murali,et al.  Structure-based design of immunologically active therapeutic peptides , 1998, Immunologic research.

[9]  D. O’Rourke,et al.  Trans receptor inhibition of human glioblastoma cells by erbB family ectodomains. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[10]  N. Hynes,et al.  ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.

[11]  D. O’Rourke,et al.  Inhibition of p185neu kinase activity and cellular transformation by co-expression of a truncated neu protein. , 1996, Oncogene.

[12]  W. Muller,et al.  Mutations affecting conserved cysteine residues within the extracellular domain of Neu promote receptor dimerization and activation. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Y. Yarden,et al.  Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. , 1996, The EMBO journal.

[14]  C. Ward,et al.  Insulin and epidermal growth factor receptors contain the cysteine repeat motif found in the tumor necrosis factor receptor , 1995, Proteins.

[15]  C. Heldin,et al.  Dimerization of cell surface receptors in signal transduction , 1995, Cell.

[16]  M Kiessling,et al.  Amplification of the epidermal‐growth‐factor‐receptor gene correlates with different growth behaviour in human glioblastoma , 2007, International journal of cancer.

[17]  L. Cantley,et al.  A neu acquaintance for ErbB3 and ErbB4: A role for receptor heterodimerization in growth signaling , 1994, Cell.

[18]  W. Dougall,et al.  Kinase-deficient neu proteins suppress epidermal growth factor receptor function and abolish cell transformation. , 1994, Oncogene.

[19]  W. Dougall,et al.  Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: a mechanism of interreceptor kinase activation and transphosphorylation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[20]  G. Plowman,et al.  Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[21]  G. Plowman,et al.  Molecular cloning and expression of an additional epidermal growth factor receptor-related gene. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Greene,et al.  Intermolecular association of the p185 neu protein and EGF receptor modulates EGF receptor function , 1990, Cell.

[23]  Joseph Schlessinger,et al.  Signal transduction by receptors with tyrosine kinase activity , 1990, Cell.

[24]  M. Kraus,et al.  Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[25]  V. Brown,et al.  Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts , 1989, Cell.

[26]  D. Weiner,et al.  A point mutation in the neu oncogene mimics ligand induction of receptor aggregation , 1989, Nature.

[27]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[28]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[29]  Cori Bargmann,et al.  The neu oncogene encodes an epidermal growth factor receptor-related protein , 1986, Nature.

[30]  N. Nomura,et al.  Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor , 1986, Nature.

[31]  R. Weinberg,et al.  Molecular cloning of the neu gene: absence of gross structural alteration in oncogenic alleles. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Hermona Soreq,et al.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin , 1985, Nature.

[33]  P. Seeburg,et al.  Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells , 1984, Nature.

[34]  H. Herschman,et al.  Variants of 3T3 cells lacking mitogenic response to epidermal growth factor. , 1977, Proceedings of the National Academy of Sciences of the United States of America.